We are analyzing https://link.springer.com/article/10.1007/s00210-025-04131-w.

Title:
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy | Naunyn-Schmiedeberg's Archives of Pharmacology
Description:
The advent of immune checkpoint inhibitors (ICIs) has revolutionised cancer therapy and has led to improved outcomes for patients with many cancers. While proven inhibitors targeting programmed cell death protein 1 (PD- 1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA- 4) have had great success, new ICIs are on the horizon. However, data from clinical trials indicate that some patients develop resistance to ICIs targeting PD- 1/L1 and/or CTLA- 4 for multiple mechanisms. This gives rise to the idea that combining therapy by using multiple ICIs could help overcome this resistance through the inhibition of multiple pathways and immune checkpoints. Therefore, the new generation of immune checkpoint inhibitors opens up new therapeutic candidates for solid tumors. This review covers novel checkpoint agents, including T cell immunoglobulin and mucin domain 3 (TIM- 3), lymphocyte activating gene 3 (LAG- 3), and other promising pathways, including Ig V domain suppressor for T cell activation (VISTA). We review the underlying mechanisms of these targets, how they have been developed in the laboratory and clinic, and the initial efficacy and safety seen in ongoing trials. We also discuss combination strategies to further improve their therapeutic potential. By identifying challenges and opportunities with these new agents, this review explores the direction in which immunotherapy for solid tumors is headed and calls for further research in this emerging field.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, article, google, scholar, cas, central, cancer, cell, immune, immunol, cells, med, checkpoint, immunotherapy, tim, oncol, blockade, ctla, phase, melanoma, tumor, lag, clin, res, therapy, resistance, immunity, patients, tumors, nat, advanced, vista, combination, expression, nivolumab, antibody, antitumor, gene, sci, solid, trial, activation, human, ipilimumab, targeting, study, nature, exp, receptor, inhibitors,

Topics {✒️}

month download article/chapter galectin-9-independent ligand-binding surface tumor antigen–specific cd8+ high-risk myelodysplastic syndrome ifn-γ pathway genes acidic ph-selective ligand trans pd-l1 interaction zr-dfo-azepin-onartuzumab foxp3/nfat interaction enhances rouzbeh shams amiri intra-tumoural trbv6-6 variants constitutive clathrin-mediated endocytosis pd-1/pd-l1 blockade monotherapy single-cell rna-seq targeting stat3-vista axis peripheral t-cell tolerance human cd4 n-terminal immune-checkpoint protein vista phase ib/ii trial restore anti-tumor immunity anti-pd-1 antibody toripalimab cd80 cis-heterodimer triggers small-cell lung cancer small-cell lung cancer article naunyn-schmiedeberg' higher-risk mds treated anti-pd-l1 antibody anti-tim3 antibody promotes v-domain ig suppressor anti-lag-3 antibody lbl-007 α-pd-l1 antibody enhances t-cell function full article pdf andrews lp mhc class ii1 cancer chemo-immunotherapy resistance pembrolizumab-based combination therapy immune checkpoint modulators cd33-positive myeloid cells lymphocyte activation gene-3 lymphocyte activation gene-31 tumor-expressed ido recruits tumor-infiltrating regulatory lag-3-targeted therapy ochoa de olza accepted manuscript version cd4-related molecule suppress tumor aggression t-cell immunoglobulin open-ended story

Questions {❓}

Böger C et al (2017) The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy?
Musielak B, Kocik J, Skalniak L, Magiera-Mularz K, Sala D, Czub M, et al (2019) CA-170–a potent small-molecule PD-L1 inhibitor or not?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
         description:The advent of immune checkpoint inhibitors (ICIs) has revolutionised cancer therapy and has led to improved outcomes for patients with many cancers. While proven inhibitors targeting programmed cell death protein 1 (PD- 1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA- 4) have had great success, new ICIs are on the horizon. However, data from clinical trials indicate that some patients develop resistance to ICIs targeting PD- 1/L1 and/or CTLA- 4 for multiple mechanisms. This gives rise to the idea that combining therapy by using multiple ICIs could help overcome this resistance through the inhibition of multiple pathways and immune checkpoints. Therefore, the new generation of immune checkpoint inhibitors opens up new therapeutic candidates for solid tumors. This review covers novel checkpoint agents, including T cell immunoglobulin and mucin domain 3 (TIM- 3), lymphocyte activating gene 3 (LAG- 3), and other promising pathways, including Ig V domain suppressor for T cell activation (VISTA). We review the underlying mechanisms of these targets, how they have been developed in the laboratory and clinic, and the initial efficacy and safety seen in ongoing trials. We also discuss combination strategies to further improve their therapeutic potential. By identifying challenges and opportunities with these new agents, this review explores the direction in which immunotherapy for solid tumors is headed and calls for further research in this emerging field.
         datePublished:2025-04-11T00:00:00Z
         dateModified:2025-04-11T00:00:00Z
         pageStart:1
         pageEnd:28
         sameAs:https://doi.org/10.1007/s00210-025-04131-w
         keywords:
            VISTA
            LAG- 3
            TIM- 3
            Solid tumors
            Immunotherapy
            Pharmacology/Toxicology
            Neurosciences
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00210-025-04131-w/MediaObjects/210_2025_4131_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00210-025-04131-w/MediaObjects/210_2025_4131_Fig2_HTML.png
         isPartOf:
            name:Naunyn-Schmiedeberg's Archives of Pharmacology
            issn:
               1432-1912
               0028-1298
            type:
               Periodical
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Amirhoushang Poorkhani
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mahboubeh Tajaldini
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Farahnazsadat Ahmadi
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Arash Tahmasebifar
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mahboobeh Azadehrah
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Malihe Azadehrah
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Amir Ghamoushiramandi
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rouzbeh Shams Amiri
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Vahid Khori
               affiliation:
                     name:Golestan University of Medical Sciences
                     address:
                        name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
      description:The advent of immune checkpoint inhibitors (ICIs) has revolutionised cancer therapy and has led to improved outcomes for patients with many cancers. While proven inhibitors targeting programmed cell death protein 1 (PD- 1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA- 4) have had great success, new ICIs are on the horizon. However, data from clinical trials indicate that some patients develop resistance to ICIs targeting PD- 1/L1 and/or CTLA- 4 for multiple mechanisms. This gives rise to the idea that combining therapy by using multiple ICIs could help overcome this resistance through the inhibition of multiple pathways and immune checkpoints. Therefore, the new generation of immune checkpoint inhibitors opens up new therapeutic candidates for solid tumors. This review covers novel checkpoint agents, including T cell immunoglobulin and mucin domain 3 (TIM- 3), lymphocyte activating gene 3 (LAG- 3), and other promising pathways, including Ig V domain suppressor for T cell activation (VISTA). We review the underlying mechanisms of these targets, how they have been developed in the laboratory and clinic, and the initial efficacy and safety seen in ongoing trials. We also discuss combination strategies to further improve their therapeutic potential. By identifying challenges and opportunities with these new agents, this review explores the direction in which immunotherapy for solid tumors is headed and calls for further research in this emerging field.
      datePublished:2025-04-11T00:00:00Z
      dateModified:2025-04-11T00:00:00Z
      pageStart:1
      pageEnd:28
      sameAs:https://doi.org/10.1007/s00210-025-04131-w
      keywords:
         VISTA
         LAG- 3
         TIM- 3
         Solid tumors
         Immunotherapy
         Pharmacology/Toxicology
         Neurosciences
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00210-025-04131-w/MediaObjects/210_2025_4131_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00210-025-04131-w/MediaObjects/210_2025_4131_Fig2_HTML.png
      isPartOf:
         name:Naunyn-Schmiedeberg's Archives of Pharmacology
         issn:
            1432-1912
            0028-1298
         type:
            Periodical
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Amirhoushang Poorkhani
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mahboubeh Tajaldini
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Farahnazsadat Ahmadi
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Arash Tahmasebifar
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mahboobeh Azadehrah
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Malihe Azadehrah
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Amir Ghamoushiramandi
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rouzbeh Shams Amiri
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Vahid Khori
            affiliation:
                  name:Golestan University of Medical Sciences
                  address:
                     name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical"]:
      name:Naunyn-Schmiedeberg's Archives of Pharmacology
      issn:
         1432-1912
         0028-1298
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
      name:Golestan University of Medical Sciences
      address:
         name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Amirhoushang Poorkhani
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Mahboubeh Tajaldini
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Farahnazsadat Ahmadi
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Arash Tahmasebifar
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Mahboobeh Azadehrah
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Malihe Azadehrah
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Amir Ghamoushiramandi
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      name:Rouzbeh Shams Amiri
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Vahid Khori
      affiliation:
            name:Golestan University of Medical Sciences
            address:
               name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
      name:Ischemic Disorder Research Center, Golestan University of Medical Sciences, Gorgan, Iran
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(656)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.96s.

LINK . SPRINGER . COM {}